Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| Faculty of Medicine | Other Identifier | Thammasat University, Thailand |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of this clinical is to compare treatment outcomes between continuous nebulization and intermittent therapy in the management of acute exacerbation of asthma in the emergency department(ED). Participants will random assign to either continuous or intermittent nebulization. In the continuous group, patients receive budesonide, fenoterol, ipratropium bromide, and normal saline continuously for an hour. In the intermittent group, the same medications are administer every 20 minutes for an hour. Measurements include symptom severity, respiratory rate, oxygen saturation, and pulmonary function tests. Primary endpoints are ED stay length, hospital admission, and ED revisit within 48 hours post-discharge. Adverse events are documented.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Continuous nebulization | Experimental | continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min |
|
| intermittent nebulization | Active Comparator | intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| continuous nebulization | Device | continuous nebulization using the MiniHEART-HiFlo® nebulizer containing Budesonide 1000 microgram/2 ml (3 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) and Normal saline 12 ml in the nebulizer chamber. Patients in this group will receive continuous aerosol therapy over a period of 1 hour at an oxygen flow rate of 8 L/min |
| Measure | Description | Time Frame |
|---|---|---|
| Length of ED stay | duration of ED management | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| pulmonary function test | Forced Expiratory Volume in one second(FEV1), Peak Expiratory Flow(PEF) | through study completion, an average of 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Hospital admission | through study completion, an average of 1 year | |
| ED revisit within 48 hours | revisit with acute asthma exacerbation | through study completion, an average of 1 year |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kumpol Kornthatchapong, Assoc.Prof. | Contact | +66954951555 | kump29@gmail.com |
| Name | Affiliation | Role |
|---|---|---|
| Kumpol Kornthatchapong | Faculty of Medicine, Thammasat university | Principal Investigator |
Not provided
Not provided
| Label | URL |
|---|---|
| Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department | View source |
| Continuous versus intermittent albuterol nebulization in the treatment of acute asthma | View source |
| A randomized, clinical trial comparing the efficacy of continuous nebulized albuterol (15 mg) versus continuous nebulized albuterol (15 mg) plus ipratropium bromide (2 mg) for the treatment of acute asthma |
Not provided
Not provided
| ID | Term |
|---|---|
| D004630 | Emergencies |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
randomized controlled trial (RCT)
Not provided
Not provided
Not provided
Not provided
|
| Intermittent nebulization | Device | intermittent nebulization using a nebulizer containing Budesonide 1000 microgram/2 ml (1 respules) + 1.25 mg of fenoterol and 0.5 mg of ipratropium bromide (Berodual®, 4 ml) at an oxygen flow rate of 10 L/min every 20 minutes, thrice within 1 hour |
|
| View source |